Epidermal growth factor receptor (EGFR) gene amplification and mutations are the most common oncogenic events in glioblastoma (GBM), but the mechanisms by which they promote aggressive tumor growth are not well understood. Here, through integrated epigenome and transcriptome analyses of cell lines, genotyped clinical samples, and TCGA data, we show that EGFR mutations remodel the activated enhancer landscape of GBM, promoting tumorigenesis through a SOX9 and FOXG1-dependent transcriptional regulatory network in vitro and in vivo. The most common EGFR mutation, EGFRvIII, sensitizes GBM cells to the BET-bromodomain inhibitor JQ1 in a SOX9, FOXG1-dependent manner. These results identify the role of transcriptional/epigenetic remodeling in EGFR-dependent pathogenesis and suggest a mechanistic basis for epigenetic therapy.
In Brief
Epidermal growth factor receptor (EGFR) gene amplification and mutations are the most common oncogenic events in glioblastoma (GBM). Through an integrative genomics analysis, Liu et al., identify a role for transcriptional/ epigenetic remodeling in EGFRdependent pathogenesis and suggest a mechanistic basis for epigenetic therapy.
INTRODUCTION
Growth factor receptors are frequently amplified and/or mutated in cancer (Ciriello et al., 2013; Kandoth et al., 2013; Vogelstein et al., 2013) . Growth factor receptor mutations activate intracellular signaling cascades that promote growth, at least in part, by regulating transcriptional networks . Master transcription factors (TFs) interact with cis-regulatory DNA sequences to control transcriptional repertoires that drive tumor growth and survival (Baylin and Jones, 2011; Suvà et al., 2013) . However, the mechanisms by which mutated growth factor receptors control the transcriptional machinery and alter the epigenetic landscape of cancer cells to reprogram transcription are not well understood.
Glioblastoma (GBM) is the most common primary brain cancer of adults and one of the most lethal of all human malignancies (Cloughesy et al., 2014) . The epidermal growth factor receptor (EGFR) is amplified and/or mutated in up to 60% of GBMs, promoting tumor growth and survival through persistent activation of signaling networks and metabolic reprogramming (Cloughesy et al., 2014; Furnari et al., 2015) . Currently, the impact of EGFR alteration on the transcriptional/epigenetic landscape of tumor cells is not known. Here, using global RNA-sequencing (seq) and chromatin immunoprecipitation (ChIP)-seq analysis of GBM cell lines, patient-derived tumor cells in neurosphere culture and clinical biopsies genotyped for EGFR mutation status, we identify a SOX9 and FOXG1-dependent transcriptional regulatory network that remodels the enhancer activation landscape to drive EGFRvIII-dependent tumorigenesis in vitro and in vivo and sensitizes GBM cells to the bromodomain and extra-terminal (BET)bromodomain inhibitor JQ1. These results link oncogeneinduced signaling with a highly specific program of epigenetic remodeling, suggesting that global epigenetic analysis of specific oncogene mutations may provide new therapeutic insights.
RESULTS

Integrative Analyses of Chromatin Landscape Induced by EGFRvIII
We analyzed histone H3 lysine 4 monomethylation (H3K4me1) and histone H3 lysine 27 acetylation (H3K27ac)-two histone modifications associated with poised and active enhancers (Creyghton et al., 2010; Heintzman et al., 2007; Rada-Iglesias et al., 2011) -by ChIP-seq in isogenic U87 GBM cells with, or without, stable expression of the ligand-independent activated EGFR mutation, EGFRvIII. This analysis revealed 2,245 putative enhancers that were specifically activated in EGFRvIII-expressing GBM cells ( Figure 1A) . The activation state of these enhancers was not changed by the addition of serum, which contained growth factors that could activate other cell surface receptors ( Figure 1A) .
To gain insight into the regulation of EGFRvIII-specific transcription that might be regulated by these putative enhancers, we performed RNA-seq ( Figure 1B) . The EGFRvIII-activated enhancers identified by H3K4me1 and H3K27ac ChIP-seq were significantly enriched near EGFRvIII-upregulated transcripts, suggesting the presence of a coordinated, EGFRvIII-regulated, transcriptional network ( Figure 1C ). Analysis of TF recognition motifs within EGFRvIII-activated enhancers showed that binding sites for many of the 41 TFs upregulated in EGFRvIII-expressing GBM cells were highly enriched ( Figure S1A ). In particular, motifs for the FOX and SOX family of TFs were among the most highly enriched motifs ( Figure 1D ). SOX9 and FOXG1 transcripts, which have been implicated in brain development and are thought to play a role in cancer (Guo et al., 2012; Rani et al., 2013; Seoane et al., 2004; Swartling et al., 2012; Verginelli et al., 2013; Wang et al., 2012) , were both highly elevated by EGFRvIII expression ( Figure 1B) . Therefore, we set out to determine whether EGFRvIII regulates SOX9 and FOXG1 expression and to study its functional importance.
EGFRvIII Activates the Transcription of SOX9 and FOXG1
In GBM cells treated with the EGFR tyrosine kinase inhibitor erlotinib, we detected a marked decrease in H3K27ac at putative enhancers near SOX9 and FOXG1 (Figure 2A) . The erlotinibsensitive H3K27ac peak near FOXG1 forms long-range chromatin looping with the FOXG1 promoter, as evidenced by a circularized chromosome confirmation capture (4C-seq) experiment, supporting its role as a FOXG1 enhancer ( Figure S2A ). We examined the effect of EGFRvIII on SOX9 and FOXG1 mRNA and protein levels in multiple GBM cell line contexts. In U87 GBM cells, EGFRvIII expression dramatically increased SOX9 and FOXG1 transcript and protein levels ( Figures 1B and 2B) , which was inhibited by erlotinib ( Figure S2B ). The mTOR kinase inhibitor torin1 and the MEK inhibitor U0126 also reduced SOX9 and FOXG1 levels, suggesting that EGFRvIII controls expression of these TFs through downstream signaling (Figures S2B and S2C) . To determine whether wild-type EGFR and mutant EGFR, EGFRvIII, differentially regulate SOX9 and FOXG1, we generated a small interfering (si)RNA construct targeting exon 9 of EGFR, which knocks down both wild-type EGFR and EGFRvIII, and an siRNA construct targeting exon 2, a region deleted in EGFRvIII, which only knocks down wild-type EGFR expression ( Figure 2C ). As shown in Figure 2D , knockdown of EGFRvIII, but not wild-type EGFR alone, resulted in significantly reduced SOX9 and FOXG1 transcript levels. To test whether EGFRvIII's effect on SOX9 and FOXG1 depended on its kinase activity, we introduced a kinase dead EGFRvIII construct (EGFRvIII-KD; Figure 2E ) Huang et al., 1997) . In U87 GBM cells, EGFRvIII, but not kinase dead EGFRvIII, significantly elevated SOX9 and FOXG1 transcript levels in an erlotinib-sensitive fashion (Figure 2F) , indicating that: (1) the observed effect of EGFRvIII on SOX9 and FOXG1 transcription was not due to exogenous EGFRvIII expression, and (2) the effect of EGFRvIII on SOX9 and FOXG1 expression was dependent on EGFRvIII kinase activity. To confirm the effect of EGFRvIII in different GBM cell line contexts, we expressed EGFRvIII under the control of a doxycycline inducible promoter in LN229 GBM cells and expressed EGFRvIII under the control of a doxycycline repressible promoter in U373 GBM cells. EGFRvIII potently upregulated SOX9 and FOXG1 protein expression in both cell lines ( Figure 2G ). To determine whether endogenously expressed EGFRvIII similarly regulates SOX9 and FOXG1, we analyzed GBM6 patient-derived cells in neurosphere culture (Nathanson et al., 2014; Sarkaria et al., 2007) . Erlotinib treatment greatly reduced SOX9 and FOXG1 protein expression in GBM6 cells, demonstrating that endogenously expressed and U87EGFRvIII cells. The presence of EGFRvIII results in the activation and silencing of distinct sets of enhancers. Note that these potential enhancers show little response to 10% fetal bovine serum (FBS), which contains various growth factors. (B) Heat map of RNA-seq data shows the transcript levels of TF genes differentially expressed between U87 and U87EGFRvIII cells (see also Figure S1 ). (C) The number of EGFRvIII-responsive enhancers near random gene sets (blue), as compared to a set of EGFRvIII-specific genes (red). (D) Enrichment scores for known transcription factor motifs at EGFRvIII-responsive enhancers. FOX and SOX motifs are indicated. See also Figure S1 and Table S4 .
EGFRvIII also regulates SOX9 and FOXG1 through its kinase activity in a non-engineered cell context ( Figures 2H and 2I ).
SOX9 and FOXG1 Interact with EGFRvIII-Responsive Enhancers
To determine whether SOX9 and FOXG1 bind to EGFRvIIIresponsive enhancers, we performed ChIP-quantitative (q) PCR on two informative genes, FOXF1 and TFAP2c, using antibodies directed against SOX9 and FOXG1. We focused on these two genes because: (1) they are near EGFRvIII-responsive enhancers (defined by H3K27Ac and H3K4me1, being Figure S2 and Table S3 .
very high at enhancers near these genes in U87EGFRvIII cells and silent in U87 cells), (2) their expression was greatly elevated by the expression of EGFRvIII, and (3) SOX9 or FOXG1 knockdown abrogated their mRNA expression. As shown in Figure 3A , SOX9 and FOX1 both bind to EGFRvIII-responsive enhancers near these two EGFR-regulated genes. Furthermore, we performed ChIP-qPCR on the SOX9 and FOXG1 loci, demonstrating that SOX9 and FOXG1 both bind to enhancers that may regulate them, thus providing compelling evidence for autoregulation ( Figures 3B and 3C ). Careful inspection of the ChIP-qPCR data suggested that FOXG1 might also cross regulate SOX9. FOXG1 knockdown reduced SOX9 transcript and protein levels, and vice versa, raising the possibility of a more complex form of cross regulation ( Figures S3A and S3B ). A random forest classifier demonstrated that genetic alteration of growth factor receptors accurately predicted the levels of SOX9 (area under curve [AUC] = 0.94, p = 2.3 3 10 À15 , Z test) and FOXG1 (AUC = 0.83, p < 1 3 10 15 , Z test), in GBM clinical samples driven largely by genetic alterations of EGFR (Figures 4C, S4E, and S4F). Furthermore, FGFR3 overexpression, which is associated with gene amplification and/or mutation (Parker et al., 2013; Singh et al., 2012) , was associated with elevated SOX9 levels in the TCGA clinical GBM samples. Ligand-induced FGFR3 activation increased SOX9 levels in vitro (Figures S4E and S4G) . Taken together with the mechanistic data showing that EGFRvIII promotes SOX9 and FOXG1 (Figure 2) , these results indicate a strong association between EGFR genetic alterations and SOX9 and FOXG1 expression, as well as an association between FGFR3 and SOX9, in GBM. This association was also confirmed at the protein level. An immunohistochemical analysis of GBM tissue microarrays demonstrated significant correlations between phospho-EGFR, SOX9, and FOXG1 proteins, all of which were correlated with each other and with tumor cell proliferation rate, as measured by Ki67 staining . Analysis of TCGA data from other tumor types also demonstrated elevated SOX9 and FOXG1 in association with amplification of various growth factor receptors in a variety of cancers (Figures S4H and S4I; Table S1 ), suggesting that SOX9 and FOXG1 may be common transcriptional effectors downstream of growth factor alterations in multiple cancer types.
To further verify if the growth factor induced transcriptional program and epigenetic remodeling identified in the above cell models is present in GBM tumors, we performed ChIP-seq to profile the H3K4me1 and H3K27ac status of regulatory DNA sequences in a set of GBM clinical samples. There were 14 frozen GBM tissue samples that were screened for quality and six were selected based upon the presence of greater than 70% tumor cells in the tissue sample (Table S2 ). This included four GBMs with EGFR amplification and EGFRvIII mutation and two GBMs with elevated FGFR3 transcript expression ( Figure S4J ). We also performed H3K4me1 and H3K27ac ChIP-seq on one low grade glioma bearing no receptor tyrosine kinase (RTK) mutations, but containing an IDH1 R132H mutation (Table S2 ). As a basis of comparison, we obtained H3K27ac ChIP-seq profiles from six different normal brain regions. There were two distinct clusters of growth factor-associated enhancers that were detected in the GBMs, which were not found in either the IDH1 mutant low grade glioma or in the normal brain samples ( Figure 4D ). These putative EGFR/FGFR3-activated enhancers were significantly enriched for binding sequence motifs of the SOX and FOX family of TFs ( Figure 4E ) and are located near genes differentially expressed between EGFRvIII + and EGFR euploid GBMs (Figure 4F ). Taken together, these results indicate the presence of a coordinated transcriptional program with epigenetic remodeling downstream of RTK genetic alterations in clinical GBM samples.
SOX9 and FOXG1 Promote GBM In Vitro and In Vivo
To determine the functional role of SOX9 and FOXG1 in EGFR-vIII-dependent tumor growth, we generated GBM cells stably expressing short hairpin (sh)RNAs targeting SOX9 and FOXG1 and performed ChIP-seq analysis to determine the effect of these knockdowns on the activation state of EGFRvIII-responsive enhancers. Knock down of either TF significantly decreased H3K27 acetylation and H3K4 monomethylation of EGFRvIIIresponsive enhancers ( Figures 5A and 5B ). Further, knock down of either SOX9 or FOXG1 severely impaired the growth of U87EGFRvIII cells in culture and almost completely blocked colony formation in soft agar . In vivo, SOX9 or FOXG1 knockdown resulted in a marked delay in tumor development along with significant reductions in tumor sizes in mice bearing SOX9 or FOXG1-knockdown tumors and this was associated with significantly longer survival (Figures 5D-5F and S5D-S5L).
To identify the global transcriptional repertoires controlled by SOX9 and FOXG1, we performed RNA-seq analysis of U87EGFRvIII cells with or without shRNA knock down of SOX9 or FOXG1. This analysis identified 993 and 1,920 genes whose expression was markedly reduced by SOX9 and FOXG1 knockdown, respectively, including 376 genes that are regulated by both TFs ( Figure 5G ). These 376 genes were highly overrepresented in gene ontologies that are associated with glioma and other cancer types, indicating a potentially important oncogenic function ( Figure 5H ). Taken together, these results indicate that SOX9 and FOXG1 collaborate to control a subset of EGFRvIIIregulated genes in GBM.
To identify actionable transcriptional programs regulated by SOX9 or FOXG1, we performed gene set enrichment analysis (GSEA) on the transcriptomes of SOX9/FOXG1 knockdown cells. This analysis indicated significant enrichment for Figure S3 and Table S3 .
previously identified c-MYC target genes and EGFR-regulated genes ( Figure 5I ), suggesting that SOX9 and FOXG1-coregulated genes play a role in promoting EGFR-dependent tumor cell growth.
EGFRvIII Sensitizes GBM Cells to JQ1-Induced Cell Death through SOX9 and FOXG1 c-MYC expression, and transcription of its target genes, is regulated by BRD4, a BET protein family member, which acts as a (Table S1 ) can accurately predict SOX9 and FOXG1 levels in GBM using a random forest classifier. (D) Heat map of ChIP-seq using tissue samples, including six GBMs (four expressing high levels of EGFR and two expressing high levels of FGFR3; Figure S4J ), one low grade glioma (which carries IDH1 R132H mutation), and six normal brain tissues ( Figure S4 and Tables S2 and S4. transcriptional cofactor (Shi and Vakoc, 2014) . Notably, among the BET family members, BRD4 transcript level was significantly correlated with that of SOX9 and FOXG1 in the TCGA database of GBMs ( Figures 6A and 6B) . BRD4 transcription was also significantly increased in the classical GBM subtype that is enriched for EGFR-genetic alterations ( Figure 6C consistent with recent evidence that c-MYC is critical for EGFRvIIIdependent tumorigenesis Masui et al., 2013) .
Recent studies have shown that JQ1 is effective in suppressing the growth of certain cancers that rely on amplified transcription for maintaining their oncogenic state (Lin et al., 2012; Lové n et al., 2013) . Therefore, we asked whether EGFRvIII sensitizes GBMs to JQ1 and whether this is mediated through the SOX9 and FOXG1 transcriptional network. In U87 GBM cells, the presence of EGFRvIII significantly increased the amount of apoptosis in response to JQ1 (Figures 6H and S6B) . shRNAs targeting SOX9, FOXG1, or BRD4 all reversed the EGFRvIII-depen-dent apoptotic sensitivity to JQ1 ( Figure 6H ), demonstrating that EGFRvIII-expressing GBM cells have heightened apoptotic responsiveness to JQ1, which is mediated by SOX9 and FOXG1 and is BRD4-dependent. This heightened response to JQ1 is attributable to the kinase activity of EGFRvIII, because no difference was observed in the level of JQ1-induced cell death in U87 GBM cells expressing kinase dead EGFRvIII (Figure 6I) . The effect of EGFRvIII on sensitizing GBM cells to JQ1 was also observed in LN229 and U373 GBM cells in which EGFRvIII was under the control of doxycycline-regulatable promoters (LN229 tet-on and U373 tet-off; Figures 6J and 6K) . To further confirm these findings, we applied a live-cell activated caspase-3/7 imaging assay to assess whether this JQ1mediated apoptosis was correlated with increased caspase activation and/or EGFRvIII kinase activity. By this method, JQ1 had only minor effects on U87 cells. In contrast, JQ1 treatment caused dose-dependent increases in caspase activity levels in both U87 EGFRvIII and kinase dead EGFRvIII cells. However, JQ1 exerted its effects on the U87 EGFRvIII cells at significantly lower concentrations relative to those expressing the catalytically inactive mutant (Figures 7A, 7B, and S6C) . Hence, the effects of JQ1 on cell death are likely caspase-dependent and dramatically enhanced by EGFRvIII kinase activity. Furthermore, the patient-derived neurosphere cell line GBM6, which carries endogenous EGFR amplification and EGFRvIII mutation, is sensitive to JQ1-induced cell death and its viability is dependent on the expression of SOX9 and FOXG1 ( Figure 7C) .
Last, we examined the effect of JQ1, which was highly brainpenetrant ( Figure S7 ), on U87 EGFRvIII GBM growth in the brain in a mouse xenograft model. JQ1 administered twice daily at 50 mg/kg by oral gavage significantly decreased intracranial tumor growth ( Figure 7D ).
DISCUSSION
Cancer arises from the intertwined processes of spontaneous somatic mutation and sequential selection for aggressive subclones (Stratton, 2011) . Cancer is also an epigenetic disease. Mutations in TFs, chromatin regulators, and even non-coding intergenic sequences, including putative super-enhancer sequences, contribute to tumor formation and progression Mansour et al., 2014) , consistent with the critical role for epigenetic alterations in tumorigenesis. There is also a complex interplay between genetic and epigenetic mechanisms in cancer, as oncogenes remodel cis-regulatory and TF networks to promote tumor formation and progression (Baylin and Jones, 2011; Hanahan and Weinberg, 2011; Lee and Young, 2013; Rivera and Ren, 2013; Shen and Laird, 2013; Suvà et al., 2013) . Currently, the mechanisms by which oncogenic mutations remodel the epigenome are incompletely understood.
Here, we set out to determine the impact of EGFR mutations, one of the signature molecular lesions in GBM, on epigenetic reprogramming. GBM is a particularly compelling tumor for this type of integrated analysis. GBM is one of the most deeply genomically characterized forms of cancer (Lawrence et al., 2014) , revealing a remarkably high prevalence of EGFR amplification and mutations (Brennan et al., 2013) , even at the single cell level . Extensive research has begun to identify the signaling pathways and metabolic events by which EGFR mutations promote GBM pathogenesis (Cloughesy et al., 2014; Furnari et al., 2015) . However, the global impact of EGFR mutations on epigenetic remodeling in GBM is not understood. Therefore, we applied global RNA-seq and ChIP-seq approaches to GBM cell lines, patient-derived tumor cells in neurosphere culture, and clinical biopsies genotyped for EGFR mutation status to interrogate the global impact of EGFRvIII on epigenetic remodeling, revealing a SOX9 and FOXG1-dependent transcriptional regulatory network that remodels the enhancer activation landscape to drive EGFRvIII-dependent tumorigenesis.
There are likely to be many other epigenetic states and TFs that are critical for GBM pathogenesis, including the ones recently described that control the stem-like state and in vivo tumor propagation capacity (Rheinbay et al., 2013; Suvà et al., 2014) . We have previously shown that endogenously expressed EGFRvIII does not appear to alter the stem-like state of GBM cells (Nathanson et al., 2014) . Thus, it is not surprising that our analyses might not pick up those previously detected critical TF networks involved in stem cell fate reprogramming. Instead, our study enabled us to detect a critical transcription network and epigenetic state by which EGFRvIII promotes tumor formation and progression.
EGFR mutations, including EGFRvIII, are compelling drug targets in GBM. However, EGFR tyrosine kinase inhibitors have failed to show durable benefit for GBM patients in part because it has not been possible to achieve sufficient intratumoral drug levels to adequately inhibit EGFR phosphorylation (Vivanco et al., 2012) . This failure of target inhibition results in feedback activation of other RTKs such as PDGFRb to maintain downstream signal flux and/or reversible loss of EGFRvIII from extrachromosomal DNA to promote drug resistance Furnari et al., 2015; Nathanson et al., 2014) . Until new drug formulations or better dosing approaches are developed that safely achieve higher dose levels and more effectively target inhibition within the tumor in the brain, alternative therapeutic strategies for EGFR activated GBMs need to be considered.
Our finding that EGFRvIII sensitizes GBM cells to the BET-bromodomain inhibitor, suggests a potentially clinically actionable ''precision medicine'' strategy. We find that EGFRvIII enhances JQ1-dependent apoptosis via its effect on SOX9 and FOXG1, which converge to control BRD4 and c-MYC protein levels. JQ1 treatment results in a near total loss of c-MYC protein on western blot ( Figure 6D ), whereas the decrement in c-MYC transcript is more modest (Figure S6A) . Similarly, SOX9 and FOXG1 knock downs precipitously lower c-MYC protein levels ( Figures  6F and 6G) , despite relatively modest effects on expression of c-MYC transcript. These observations, although limited in scope, raise the possibility that SOX9 and FOXG1 may regulate c-MYC protein translation and/or stability in a BRD4-(or other BET bromodomain protein) dependent fashion. Future studies will be needed to test this possibility, to determine if it is detected in other cell contexts, and to identify a potential underlying mechanism.
Many cancer types depend on c-MYC for growth and proliferation, and c-MYC is a common target for amplification in many of these tumors Lin et al., 2012; Nie et al., 2012) . In contrast in GBM, c-MYC is rarely amplified or mutated (Brennan et al., 2013) . We have previously demonstrated that EGFRvIII signaling through mTORC1 enhances c-MYC activity through the alternative splicing of the c-MYC heterodimerization partner Max to generate Delta Max, a gain of function variant . Further, EGFRvIII controls c-MYC protein level through a FOXO 1-, 3-acetylation signaling cascade . Thus, our finding that EGFRvIII regulates c-MYC levels through the SOX9 and FOXG1 transcriptional activity further demonstrates the critical nature of c-MYC in EGFRvIIIdependent GBM pathogenesis, expands our understanding of its regulation, and potentially explains the enhanced apoptotic sensitivity to JQ1. It is also interesting to speculate that BRD4 and elevated c-MYC activity downstream of growth factor receptor mutations in adult GBMs may be a common pathogenic mechanism shared with pediatric high grade gliomas that have H3K27M mutations, but lack growth factor receptor alterations (Herz et al., 2014; Lewis et al., 2013; Sturm et al., 2014) .
EXPERIMENTAL PROCEDURES
Cell Lines and Tissue Samples
The human glioma cell line U87 (or U-87MG) was purchased from ATCC. U87EGFRvIII, U87EGFRvIII-KD, LN229_teton_vIII, U373_tetoff_vIII, and GBM6 cell lines were described before Nathanson et al., 2014; Wang et al., 2006) . Tumor samples were obtained from University of California, Los Angeles (UCLA) Brain Tumor Translational Resource. Normal brain tissues were obtained from the National Institute of Child Health and Human Development (NICHD) Brain Bank for Developmental Disorders. Ethics approval was obtained from the UCLA for use of the GBM tumor samples and from the University Health Network and the Hospital for Sick Children for use of the normal brain tissues.
RNA-Seq
Total RNA was extracted from one-two million cells cultured in petri dish or 50-100 mg of tissue using the RNeasy mini kit (QIAGEN). There were 5$10 mg of total RNA that were used to prepare RNA-seq libraries according to Illumina protocol. There were 4-6 libraries that were mixed for multiplexed pair-end sequencing using Illumina HiSeq 2000 (Illumina).
ChIP-Seq and ChIP-qPCR
ChIP was performed as previously described (Heintzman et al., 2007) . Immunoprecipitated DNA was purified after phenol extraction and was used for qPCR (KAPA Biosystems) or for preparing barcoded high throughput sequencing libraries according to Illumina protocols with minor modifications. There were 4-12 library preps that were mixed for multiplexed single-read sequencing using Illumina Hi-seq 2000 (Illumina). Antibodies used for ChIP were polyclonal rabbit anti-H3K27ac (Active Motif, Cat#39133), polyclonal rabbit anti-H3K4me3 (Active Motif, Cat#39159), polyclonal rabbit anti-H3K4me1 (Abcam, Cat#8895), monoclonal rabbit IgG (Abcam, Cat#ab172730), polyclonal rabbit anti-SOX9 (Millipore, Cat#AB5535), and polyclonal rabbit anti-FOXG1 (Pierce, Cat# PA5-26794).
ChIP-Seq Analysis
For a given locus, histone modification enrichment is quantified as E = log 2 (ChIP RPKM / input RPKM), where RPKM is defined as the number of reads per kilobase of locus per million mapped reads, in either ChIP or input samples. To avoid division by zero, a pseudocount of 0.05 is added to both numerator and denominator. Given a set of differentially expressed genes, we created a set of bins ± 500 kb from the transcription start sites of these genes. We also repeated this process to create 5,000 random sets of bins corresponding to the same number of random genes. Given a set of enhancers, we assessed enrichment by overlapping with bins of differentially expressed genes and comparing with the overlap for random bin sets. Motif finding was performed using Homer v4.2 (Heinz et al., 2010) .
RNA-Seq Analysis
For pairwise comparisons between two sets of samples, the number of sense exonic reads were quantified and input to edgeR (Robinson et al., 2010) to normalize and call differentially expressed genes at a p value cutoff of 0.05. To perform GSEA of RNA-seq data on U87EGFRvIII shSOX9 or U87EGFRvIII shFOXG1 compared to U87EGFRvIII, we represented expression of genes as the mean of RPKM values from biological replicates, calculated the log ratio of knockdown to U87EGFRvIII cells, and ran GSEA v2.1.0 (Subramanian et al., 2005) .
TCGA Data Analysis
Processed TCGA data were downloaded through the TCGA data portal, and mapped RNA-seq BAM files were acquired through the Cancer Genomics Hub (https://cghub.ucsc.edu/). The EGFR status of TCGA samples are designated as euploid, regionally amplified, focally amplified, or EGFRvIII based on annotations previously published (Brennan et al., 2013) . Specifically, EGFRvIII samples are samples with non-zero D2-7 values, and euploid / regionally amplified / focally amplified samples are non-EGFRvIII samples labeled as ''Euploid'' / ''Regional gain'' / ''Focal Amplification.'' Random forest analysis was performed using the TreeBagger function defined in Matlab. Given the expression of RTKs known to be amplified in a given cancer type as described in the TCGA Copy Number Portal (Mermel et al., 2011) , the random forest was first trained and then used to predict whether each sample is a high (top 100) or low (bottom 100) expresser of SOX9/FOXG1.
Intracranial Xenograft
Athymic nu/nu mice 5 weeks of age were purchased from Harlan Sprague Dawley Inc. There were 1 3 10 5 U87EGFRvIII_iRFP720 cells in 5 ml of phosphate-buffered saline (PBS) that were intracranially injected to the mouse brain (Ozawa and James, 2010) . Tumor growth was monitored using an FMT 2500 Fluorescence Tomography System (PerkinElmer). For drug treatment studies, vehicle (10% of hydroxypropyl beta cyclodextrin, Sigma-Aldrich Cat#: C0926-10G) or JQ1 (5 mg/ml) were administered to mice (10 ml per gram of body weight, or 50 mg/kg) via gavage twice daily starting from the sixth day post-injection. All procedures have been reviewed and approved by the Institutional Animal Use and Care Committee at University of California San Diego.
ACCESSION NUMBERS
The ChIP-seq and RNA-seq data reported in this study have been deposited with the Gene Expression Omnibus under the accession GEO ID: GSE72468. Table S2 ).
SUPPLEMENTAL INFORMATION
Supplemental Information includes
See also Table S1. of JQ1 in female nu/nu mice at 50 mg per kg body weight, drug concentrations in the plasma and the brain were measured by LC/MS at the indicated times. JQ1 exhibited high brain penetration with a maximum brain concentration of ~20 µM at 0.5 hr and a half-life of ~1 hr in both plasma and brain. Experiment was performed by WuXi AppTec, Shanghai, China. Table S3 and Table S4 are Excel spreadsheets attached to this manuscript. 
Supplementary Tables
Supplemental Experimental Procedures
Cell Culture
Cells were cultured at 37 °C in 5% CO 2 , in Dulbecco's Modified Eagle Media (DMEM, Cellgro)
supplemented with 10%FBS (Hyclone) and 1% penicillin/streptomycin/glutamine (Invitrogen).
Serum-starved cells were obtained by culturing cells in DMEM for 24 hours. For drug treatment in vitro, cells were seeded in DMEM+0.5% FBS. DMSO or small compound stocks were added to culture media the next day. Drug used include: erlotinib hydrochloride (Selleck), U0126
(Millipore), torin1 (Selleck). JQ1 (Santai Labs).
High Throughput Sequencing Read Mapping
ChIP-seq experiments were mapped to human genome build hg18 using Bowtie v0.12.5 (Langmead et al., 2009 ) with the following options: "-v 3 -m 1 --best -strata". H3K27ac and input
ChIP-seq experiments in normal tissue were obtained from the Roadmap Epigenomics Mapping Consortium (GSE17312) and lifted over from hg19 to hg18. PCR duplicates were removed with the Picard tool (http://broadinstitute.github.io/picard). Paired-end RNA-seq experiments were mapped using Tophat v1.4.0 ) with the following parameters: "-g 1 --library-type=fr-firststrand". 4C-Seq data were mapped using 4Cseqpipe (van de Werken et al., 2012) with the first cutter set as NlaIII (CATG) and the second cutter set as DpnII (GATC).
Enhancer Predictions
To identify putative enhancers in cell lines with H3K4me1, H3K4me3 and H3K27ac ChIP-seq data, we used RFECS (Rajagopal et al., 2013) to define an initial set and filtered for predictions with at least 1.75-fold enrichment of H3K4me1 or H3K27ac. To identify putative enhancers in tissues and tumor samples with H3K27ac data alone, we used MACS to find H3K27ac peaks (Zhang et al., 2008) . Predictions within 5kb of a transcription start site were removed. To identify enhancers specifically active in a set of EGFRvIII positive samples P = {p 1 , p 2 , …} as compared to a set of EGFRvIII negative samples N = {n 1 , n 2 , …}, we devised the following general strategy. For a given sample s and histone mark h ∈ H, let E s,h,l denote the enrichment of the histone mark for the sample at locus l compared to input, as defined above. As the histone marks examined here are enriched as punctuated peaks, we assume that the genome-wide distribution of binned (1kb) data is, to a first approximation, Gaussian. Therefore, the random variables represent the difference between histone modification enrichment between an EGFRvIII+ sample p i compared to an EGFRvIII-sample n j is , ,ℎ, = ,ℎ, − ,ℎ, , which is also Gaussian with mean and standard deviation denoted respectively as − ,ℎ and − ,ℎ .
Therefore, the random variable , ,ℎ, = , ,ℎ, − − ,ℎ − ,ℎ follows a Gaussian distribution with mean 0 and variance 1. Finally, let the test statistic ℎ, = ∑ ∑ � , ,ℎ, � 2 ∈ ∈ , which by definition follows a Chi-squared distribution with degrees of freedom equal to | | × | |. Higher values of S h,l indicate increased deviation of samples in P from samples in N for locus l. Since S h,l is unsigned, we create the indicator random variable , ,ℎ, = � 1 , ,ℎ, > 0 0 ℎ . Finally, to identify EGFRvIII-specific enhancers having a histone mark h, we keep loci l where ∑ ∑ , ,ℎ, > and where the one-sided Chi-Squared p-value for ℎ, is less than , which is determined empirically with randomized data such that corresponds to a false discovery rate of F. For the cell line comparison of two U87vIII and two U87 samples, we let = 3 and F = 10%. For the more extensive comparison of six tumor biopsies and seven control specimens, we let = 0.5 × | | × | | = 21 and F = 1%.
Gene Expression Analysis
Total RNA was extracted using the Qiagen RNeasy mini kit (Qiagen). For the quantitative polymerase chain reaction (qPCR) experiments, total RNA was reverse-transcribed to singlestranded cDNA using the SuperScript VILO cDNA synthesis kit (Life Technologies) and qPCR
